 Christiane Thienelt
Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 2001 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 1195 | 0.120 |
Why?
| | Lung Neoplasms | 1 | 2005 | 2679 | 0.090 |
Why?
| | Agranulocytosis | 1 | 2010 | 30 | 0.080 |
Why?
| | Levamisole | 1 | 2010 | 22 | 0.080 |
Why?
| | Heparin | 1 | 2011 | 249 | 0.070 |
Why?
| | BRCA2 Protein | 1 | 2009 | 68 | 0.070 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 64 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Cocaine | 1 | 2010 | 162 | 0.070 |
Why?
| | Venous Thromboembolism | 1 | 2011 | 330 | 0.060 |
Why?
| | Anticoagulants | 1 | 2011 | 751 | 0.060 |
Why?
| | Cetuximab | 1 | 2005 | 111 | 0.060 |
Why?
| | Carboplatin | 1 | 2005 | 168 | 0.050 |
Why?
| | Exanthema | 1 | 2005 | 86 | 0.050 |
Why?
| | Area Under Curve | 1 | 2005 | 334 | 0.050 |
Why?
| | Paclitaxel | 1 | 2005 | 261 | 0.050 |
Why?
| | Fatigue | 1 | 2005 | 367 | 0.050 |
Why?
| | Survival Analysis | 1 | 2005 | 1386 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2005 | 638 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1730 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2005 | 1492 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2030 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2005 | 1005 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2005 | 1514 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2009 | 2420 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2005 | 5478 | 0.030 |
Why?
| | Time Factors | 1 | 2005 | 7173 | 0.030 |
Why?
| | Intermittent Pneumatic Compression Devices | 1 | 2011 | 4 | 0.020 |
Why?
| | Organizational Case Studies | 1 | 2011 | 69 | 0.020 |
Why?
| | Personnel, Hospital | 1 | 2011 | 30 | 0.020 |
Why?
| | Reimbursement, Incentive | 1 | 2011 | 42 | 0.020 |
Why?
| | Crack Cocaine | 1 | 2010 | 9 | 0.020 |
Why?
| | Leukopenia | 1 | 2010 | 33 | 0.020 |
Why?
| | Organizational Innovation | 1 | 2011 | 119 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2005 | 11947 | 0.020 |
Why?
| | Staff Development | 1 | 2011 | 63 | 0.020 |
Why?
| | Drug Contamination | 1 | 2010 | 56 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2010 | 319 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 154 | 0.020 |
Why?
| | Adult | 3 | 2010 | 41406 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 92 | 0.020 |
Why?
| | Mastectomy, Segmental | 1 | 2009 | 107 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 139 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 277 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 187 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 310 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2009 | 173 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 654 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 411 | 0.020 |
Why?
| | Male | 3 | 2010 | 73954 | 0.010 |
Why?
| | Aged | 1 | 2005 | 26516 | 0.010 |
Why?
| | Middle Aged | 1 | 2005 | 36821 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2011 | 1598 | 0.010 |
Why?
| | Humans | 4 | 2011 | 147306 | 0.010 |
Why?
| | Quality Improvement | 1 | 2011 | 1321 | 0.010 |
Why?
| | Female | 2 | 2009 | 80081 | 0.010 |
Why?
| | Risk Assessment | 1 | 2011 | 3784 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4591 | 0.010 |
Why?
| | Prognosis | 1 | 2009 | 4384 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2011 | 3022 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6543 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 7276 | 0.010 |
Why?
| | United States | 1 | 2011 | 16313 | 0.010 |
Why?
|
|
Thienelt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|